Clonality status of multifocal lung adenocarcinomas based on the mutation patterns of EGFR and K-ras

Lung Cancer

Volumn 75, Issue 3, 2012, Pages 313-320

  Takamochi, Kazuya ^a   Oh, Shiaki ^a   Matsuoka, Joe ^a   Suzuki, Kenji ^a  

^a JUNTENDO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Adenocarcinoma; Clonality; Epidermal growth factor receptor; K ras; Multiple primary lung cancer; Pulmonary metastasis

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; GENOMIC DNA; K RAS PROTEIN;

ADULT; ARTICLE; CANCER SURVIVAL; CLINICAL ARTICLE; CLONAL VARIATION; FEMALE; GENE MUTATION; GENETIC ASSOCIATION; HUMAN; HUMAN TISSUE; LUNG ADENOCARCINOMA; MALE; MEDICAL RECORD REVIEW; MULTIFOCAL LUNG ADENOCARCINOMA; PRIORITY JOURNAL; PROGNOSIS; RETROSPECTIVE STUDY;

ADENOCARCINOMA; ADULT; AGED; FEMALE; GENES, RAS; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; MUTATION; NEOPLASMS, MULTIPLE PRIMARY; PREDICTIVE VALUE OF TESTS; RECEPTOR, EPIDERMAL GROWTH FACTOR; SURVIVAL RATE;

EID: 84856576524     PISSN: 01695002     EISSN: 18728332     Source Type: Journal    
DOI: 10.1016/j.lungcan.2011.08.007     Document Type: Article

References (30)

1. Barsky S.H., Cameron R., Osann K.E., Tomita D., Holmes E.C. Rising incidence of bronchioloalveolar lung carcinoma and its unique clinicopathologic features. Cancer 1994, 73:1163-1170.
2. Barsky S.H., Grossman D.A., Ho J., Holmes E.C. The multifocality of bronchioloalveolar lung carcinoma: evidence and implications of a multiclonal origin. Mod Pathol 1994, 7:633-640.
3. Lynch T.J., Bell D.W., Sordella R., Gurubhagavatula S., Okimoto R.A., Brannigan B.W., et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004, 350:2129-2139.
4. Paez J.G., Janne P.A., Lee J.C., Tracy S., Greulich H., Gabriel S., et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004, 304:1497-1500.
5. Eberhard D.A., Johnson B.E., Amler L.C., Goddard A.D., Heldens S.L., Herbst R.S., et al. Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib. J Clin Oncol 2005, 23:5900-5909.
6. Maemondo M., Inoue A., Kobayashi K., Sugawara S., Oizumi S., Isobe H., et al. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med 2010, 362:2380-2388.
7. Mitsudomi T., Morita S., Yatabe Y., Negoro S., Okamoto I., Tsurutani J., et al. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. Lancet Oncol 2010, 11:121-128.
8. Martini N., Melamed M.R. Multiple primary lung cancers. J Thorac Cardiovasc Surg 1975, 70:606-612.
9. Nagai Y., Miyazawa H., Huqun, Tanaka T., Udagawa K., Kato M., et al. Genetic heterogeneity of the epidermal growth factor receptor in non-small cell lung cancer cell lines revealed by a rapid and sensitive detection system, the peptide nucleic acid-locked nucleic acid PCR clamp. Cancer Res 2005, 65:7276-7282.
10. Thiede C., Bayerdorffer E., Blasczyk R., Wittig B., Neubauer A. Simple and sensitive detection of mutations in the ras proto-oncogenes using PNA-mediated PCR clamping. Nucleic Acids Res 1996, 24:983-984.
11. Yoshikawal T., Aoyagi Y., Kodama K., Kamijo T., Yonou H., Yokose T., et al. Topographical distribution of allelic loss in individual lung adenocarcinomas with lymph node metastases. Mod Pathol 2004, 17:204-213.
12. Mitsudomi T., Yatabe Y., Koshikawa T., Hatooka S., Shinoda M., Suyama M., et al. Mutations of the P53 tumor suppressor gene as clonal marker for multiple primary lung cancers. J Thorac Cardiovasc Surg 1997, 114:354-360.
13. Wang X., Wang M., MacLennan G.T., Abdul-Karim F.W., Eble J.N., Jones T.D., et al. Evidence for common clonal origin of multifocal lung cancers. J Natl Cancer Inst 2009, 101:560-570.
14. Chang Y.L., Wu C.T., Lin S.C., Hsiao C.F., Jou Y.S., Lee Y.C. Clonality and prognostic implications of p53 and epidermal growth factor receptor somatic aberrations in multiple primary lung cancers. Clin Cancer Res 2007, 13:52-58.
15. van Rens M.T., Eijken E.J., Elbers J.R., Lammers J.W., Tilanus M.G., Slootweg P.J. p53 mutation analysis for definite diagnosis of multiple primary lung carcinoma. Cancer 2002, 94:188-196.
16. Holst V.A., Finkelstein S., Yousem S.A. Bronchioloalveolar adenocarcinoma of lung: monoclonal origin for multifocal disease. Am J Surg Pathol 1998, 22:1343-1350.
17. Girard N., Ostrovnaya I., Lau C., Park B., Ladanyi M., Finley D., et al. Genomic and mutational profiling to assess clonal relationships between multiple non-small cell lung cancers. Clin Cancer Res 2009, 15:5184-5190.
18. Girard N., Deshpande C., Lau C., Finley D., Rusch V., Pao W., et al. Comprehensive histologic assessment helps to differentiate multiple lung primary nonsmall cell carcinomas from metastases. Am J Surg Pathol 2009, 33:1752-1764.
19. Sakamoto H., Shimizu J., Horio Y., Ueda R., Takahashi T., Mitsudomi T., et al. Disproportionate representation of KRAS gene mutation in atypical adenomatous hyperplasia, but even distribution of EGFR gene mutation from preinvasive to invasive adenocarcinomas. J Pathol 2007, 212:287-294.
20. Sartori G., Cavazza A., Bertolini F., Longo L., Marchioni A., Costantini M., et al. A subset of lung adenocarcinomas and atypical adenomatous hyperplasia-associated foci are genotypically related: an EGFR, HER2, and K-ras mutational analysis. Am J Clin Pathol 2008, 129:202-210.
21. Yoshida Y., Shibata T., Kokubu A., Tsuta K., Matsuno Y., Kanai Y., et al. Mutations of the epidermal growth factor receptor gene in atypical adenomatous hyperplasia and bronchioloalveolar carcinoma of the lung. Lung Cancer 2005, 50:1-8.
22. Jackson E.L., Willis N., Mercer K., Bronson R.T., Crowley D., Montoya R., et al. Analysis of lung tumor initiation and progression using conditional expression of oncogenic K-ras. Genes Dev 2001, 15:3243-3248.
23. Ji H., Li D., Chen L., Shimamura T., Kobayashi S., McNamara K., et al. The impact of human EGFR kinase domain mutations on lung tumorigenesis and in vivo sensitivity to EGFR-targeted therapies. Cancer Cell 2006, 9:485-495.
24. Politi K., Zakowski M.F., Fan P.D., Schonfeld E.A., Pao W., Varmus H.E. Lung adenocarcinomas induced in mice by mutant EGF receptors found in human lung cancers respond to a tyrosine kinase inhibitor or to down-regulation of the receptors. Genes Dev 2006, 20:1496-1510.
25. Shigematsu H., Lin L., Takahashi T., Nomura M., Suzuki M., Wistuba I.I., et al. Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers. J Natl Cancer Inst 2005, 97:339-346.
26. Chung J.H., Choe G., Jheon S., Sung S.W., Kim T.J., Lee K.W., et al. Epidermal growth factor receptor mutation and pathologic-radiologic correlation between multiple lung nodules with ground-glass opacity differentiates multicentric origin from intrapulmonary spread. J Thorac Oncol 2009, 4:1490-1495.
27. Ikeda K., Nomori H., Ohba Y., Shibata H., Mori T., Honda Y., et al. Epidermal growth factor receptor mutations in multicentric lung adenocarcinomas and atypical adenomatous hyperplasias. J Thorac Oncol 2008, 3:467-471.
28. Battafarano R.J., Meyers B.F., Guthrie T.J., Cooper J.D., Patterson G.A. Surgical resection of multifocal non-small cell lung cancer is associated with prolonged survival. Ann Thorac Surg 2002, 74:988-993. discussion 93-4.
29. Pennathur A., Lindeman B., Ferson P., Ninan M., Quershi I., Gooding W.E., et al. Surgical resection is justified in non-small cell lung cancer patients with node negative T4 satellite lesions. Ann Thorac Surg 2009, 87:893-899.
30. Tang X., Shigematsu H., Bekele B.N., Roth J.A., Minna J.D., Hong W.K., et al. EGFR tyrosine kinase domain mutations are detected in histologically normal respiratory epithelium in lung cancer patients. Cancer Res 2005, 65:7568-7572.